RU2003111948A - METHODS FOR OBTAINING NATEGLINIDE B-TYPE CRYSTALS - Google Patents

METHODS FOR OBTAINING NATEGLINIDE B-TYPE CRYSTALS

Info

Publication number
RU2003111948A
RU2003111948A RU2003111948/04A RU2003111948A RU2003111948A RU 2003111948 A RU2003111948 A RU 2003111948A RU 2003111948/04 A RU2003111948/04 A RU 2003111948/04A RU 2003111948 A RU2003111948 A RU 2003111948A RU 2003111948 A RU2003111948 A RU 2003111948A
Authority
RU
Russia
Prior art keywords
nateglinide
crystals
type crystals
type
drying
Prior art date
Application number
RU2003111948/04A
Other languages
Russian (ru)
Other versions
RU2275354C2 (en
Inventor
Митито СУМИКАВА
Макото МАРУО
Казуо МИЯЗАКИ
Сигехиро НИСИНА
Юкико МАЦУЗАВА
Original Assignee
Адзиномото Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адзиномото Ко., Инк. filed Critical Адзиномото Ко., Инк.
Publication of RU2003111948A publication Critical patent/RU2003111948A/en
Application granted granted Critical
Publication of RU2275354C2 publication Critical patent/RU2275354C2/en

Links

Claims (9)

1. Способ получения кристаллов В-типа натеглинида, по существу, свободных от кристаллов Н-типа, который включает высушивание сольватированных влажных кристаллов натеглинида при низкой температуре до тех пор, пока не останется растворителя, и осуществление их кристаллизационного превращения.1. A method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying the solvated wet nateglinide crystals at low temperature until a solvent remains, and performing their crystallization conversion. 2. Способ по п.1, при котором полученные кристаллы В-типа натеглинида являются кристаллами, в которых кристаллы Н-типа не определяются посредством DSC.2. The method according to claim 1, wherein the obtained B-type crystals of nateglinide are crystals in which H-type crystals are not detected by DSC. 3. Способ по п.1, при котором высушивание проводят при температуре 50°С или ниже.3. The method according to claim 1, wherein the drying is carried out at a temperature of 50 ° C or lower. 4. Способ по п.1, при котором высушивание проводят по существу до тех пор, пока больше не останется растворителя.4. The method according to claim 1, wherein the drying is carried out essentially until then, until there is no more solvent left. 5. Способ по п.1, при котором сольватированные влажные кристаллы являются гидратами.5. The method according to claim 1, wherein the solvated wet crystals are hydrates. 6. Способ по п.1, при котором кристаллизационное превращение осуществляют нагреванием сольватированных влажных кристаллов при 60-110°С.6. The method according to claim 1, in which the crystallization transformation is carried out by heating solvated wet crystals at 60-110 ° C. 7. Способ по п.1, при котором упомянутые две стадии высушивания названного сольватированного влажного кристалла натеглинида при низкой температуре и кристаллизационного превращения осуществляют в промышленном масштабе.7. The method according to claim 1, wherein said two stages of drying said solvated wet nateglinide crystal at low temperature and crystallization are carried out on an industrial scale. 8. Способ получения кристаллов В-типа натеглинида, по существу свободных от кристаллов Н-типа, который включает высушивание сольватированных исходных веществ, содержащих гидраты натеглинида, полученные кристаллизацией из раствора, содержащего натеглинид, при охлаждении, при температуре 50°С или ниже, до тех пор, пока не останется растворителя, и нагревание продукта при температуре 60-110°С для превращения кристаллической формы продукта в кристалл В-типа.8. A method for producing B-type crystals of nateglinide substantially free of H-type crystals, which comprises drying solvated starting materials containing nateglinide hydrates obtained by crystallization from a solution containing nateglinide, upon cooling, at a temperature of 50 ° C. or lower, to until no solvent remains, and heating the product at a temperature of 60-110 ° C to convert the crystalline form of the product into a B-type crystal. 9. Способ по п.8, при котором полученные кристаллы В-типа натеглинида являются кристаллами, в которых кристаллы Н-типа не определяются посредством DSC.9. The method of claim 8, wherein the obtained B-type crystals of nateglinide are crystals in which H-type crystals are not detected by DSC.
RU2003111948/04A 2000-10-24 2001-10-23 Methods for preparing nateglynide crystal of b-type RU2275354C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-324375 2000-10-24
JP2000324375 2000-10-24

Publications (2)

Publication Number Publication Date
RU2003111948A true RU2003111948A (en) 2004-09-20
RU2275354C2 RU2275354C2 (en) 2006-04-27

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003111948/04A RU2275354C2 (en) 2000-10-24 2001-10-23 Methods for preparing nateglynide crystal of b-type

Country Status (18)

Country Link
US (2) US20030229249A1 (en)
EP (1) EP1334964B1 (en)
JP (1) JP4225057B2 (en)
KR (1) KR100810930B1 (en)
CN (1) CN100422143C (en)
AT (1) ATE370115T1 (en)
AU (1) AU2001296001A1 (en)
BR (1) BR0114846A (en)
CA (1) CA2426745C (en)
CY (1) CY1106839T1 (en)
DE (1) DE60130014T2 (en)
DK (1) DK1334964T3 (en)
ES (1) ES2288997T3 (en)
MX (1) MXPA03003575A (en)
PT (1) PT1334964E (en)
RU (1) RU2275354C2 (en)
TW (1) TWI293290B (en)
WO (1) WO2002034713A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
KR100783306B1 (en) * 2000-10-18 2007-12-10 아지노모토 가부시키가이샤 Process for the preparation of acylphenylalanines
CN1232502C (en) * 2000-10-18 2005-12-21 味之素株式会社 Process for producing nateglinide crystal
MXPA03003685A (en) * 2000-10-24 2004-01-26 Ajinomoto Kk Nateglinide-containing preparations.
KR100829410B1 (en) * 2000-10-24 2008-05-15 아지노모토 가부시키가이샤 Nateglinide-containing hydrophilic drug preparations
WO2003087039A1 (en) * 2002-04-15 2003-10-23 Ajinomoto Co., Inc. Novel nateglinide crystal
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
CA2492644A1 (en) * 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
DE60310734T2 (en) * 2003-11-26 2007-10-11 A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A. Process for the preparation of nateglinide in the B-form
CA2563793A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
WO2006080524A1 (en) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (en) * 2006-12-26 2008-06-13 씨제이제일제당 (주) Crystalline form of nateglinide, process for the preparation thereof, and pharmaceutical composition comprising the same
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (en) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
SG11201407314XA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104603100A (en) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for treatment of inflammatory bowel disease
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN104402756B (en) * 2014-11-27 2016-08-31 天方药业有限公司 A kind of preparation method of high-purity Nateglinide
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN109369443A (en) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of new Nateglinide H crystal form

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (en) * 1985-03-27 1988-03-08 Ajinomoto Co Inc Blood sugar lowering agent
JP2508949B2 (en) * 1991-07-30 1996-06-19 味の素株式会社 Crystal of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for producing the same
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP2277517A1 (en) * 1996-11-15 2011-01-26 Ajinomoto Co., Inc. Nateglinide tablet composition
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
PL356300A1 (en) * 1999-12-28 2004-06-28 Ajinomoto Co, Inc. Oral preparations for diabetes
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
CN1232502C (en) * 2000-10-18 2005-12-21 味之素株式会社 Process for producing nateglinide crystal
KR100783306B1 (en) * 2000-10-18 2007-12-10 아지노모토 가부시키가이샤 Process for the preparation of acylphenylalanines
MXPA03003685A (en) * 2000-10-24 2004-01-26 Ajinomoto Kk Nateglinide-containing preparations.
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Similar Documents

Publication Publication Date Title
RU2003111948A (en) METHODS FOR OBTAINING NATEGLINIDE B-TYPE CRYSTALS
JP4225057B2 (en) Method for producing nateglinide type B crystal
FI872095A0 (en) FRYSFOERAONGNING.
CN108003084A (en) A kind of synthetic method of maleimide
CN110606811B (en) Synthetic method of L-serine methyl ester hydrochloride
JP2001220372A (en) Method for producing amines
CN114163353B (en) Preparation method of anisic nitrile
IS6224A (en) Process for crystallizing N- (1 (S) -ethoxycarbonyl-3-phenylpropyl) -L-alanine-N-carboxylanhydride
JPS5534115A (en) Crystallization method
JPS6354700B2 (en)
SU440060A1 (en) Method for preparing 3-aminogomoadamantane hydrochloride
JPS63284164A (en) 2-methyl-4-amino-5-aminomethylpyrimidine carbonate and its production
JPWO2003057665A1 (en) Method for producing benzenesulfonamide derivative crystal, novel crystal of intermediate and method for producing the same
JPH08134038A (en) Production of carbazinic acid
JPH0259828B2 (en)
JPS58971A (en) Manufacture of tetronic acid
SU656511A3 (en) Method of obtaining derivatives of hexahydro-4-indolinole and salts thereof
SU575023A3 (en) Method of preparing n-isopropyl-a-chloroacetanilide
JPS6015617B2 (en) Process for producing N-(1-ethyl-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamolylbenzamide and its salts
SU481600A1 (en) The method of producing amino epoxyketones
SU528030A3 (en) Method for preparing β-phenyl fatty acid derivatives
SU133886A1 (en) Method for preparing 4-amino-2,4-dimethyl-delta-2-tetrahydro-6-pyridone-4-carboxyl amide
JPS5951486B2 (en) Separation method of ammonium chloride and methylamine
JPH04234375A (en) New 2,5-dioxopiperazine compound and its production
CN113004160A (en) Synthetic method of L-serine methyl ester sulfate